8-KOther EventsExhibits & Filings

ENTEGRIS INC 8-K Report, Corporate Update (May 10, 2023)

Filed May 10, 2023For Securities:ENTG

Summary

Entegris, Inc. (ENTG) has announced the sale of its electronic chemicals business to FUJIFILM Holdings America Corporation for $700 million in cash. This strategic divestiture is subject to customary closing conditions, including regulatory approvals. The transaction is expected to provide Entegris with significant capital, which can be redeployed to further strengthen its core businesses and potentially return value to shareholders. Investors should note that the sale is contingent on regulatory clearance and other standard closing terms. While the financial impact of this divestiture will be significant, the forward-looking statements in the filing caution that actual results may differ materially due to various risks and uncertainties. Entegris' management will likely focus on integrating the remaining operations and capitalizing on future growth opportunities post-transaction.

Key Highlights

  • 1Entegris is selling its electronic chemicals business to FUJIFILM Holdings America Corporation for $700 million cash.
  • 2The transaction is subject to customary closing conditions, including regulatory approvals.
  • 3This divestiture represents a significant strategic move for Entegris, allowing potential reallocation of capital.
  • 4The sale price is subject to adjustments for cash, working capital, indebtedness, and transaction expenses.
  • 5Forward-looking statements highlight potential risks and uncertainties that could impact the transaction's closing and benefits.
  • 6The company is obligated to disclose various factors that could cause actual results to differ from expectations.

Frequently Asked Questions

Entegris, Inc. is selling its electronic chemicals business to FUJIFILM Holdings America Corporation.

The cash purchase price is $700 million, subject to customary adjustments for cash, working capital, indebtedness, and transaction expenses.

The filing does not specify an exact closing date, but states the transaction is subject to receipt of required regulatory approvals and other customary closing conditions. The forward-looking statements mention the 'anticipated timing for closing'.

Key risks include the possibility that regulatory and other approvals may not be received or satisfied on a timely basis, potential difficulties in realizing the projected benefits of the transaction, changes in the anticipated timing for closing, business disruption, and diversion of management time. Other general business risks for Entegris also apply.